Treatment of Rheumatoid Arthritis With Anti –Tumor Necrosis Factor or Tocilizumab Therapy as First Biologic Agent in a Global Comparative Observational Study

ConclusionPatients initiating tocilizumab experienced greater effectiveness and drug survival than those initiating TNFi in an observational setting.

Source: Arthritis Care and Research - September 6, 2017 Category: Rheumatology Authors: Ernest H. Choy, Corrado Bernasconi, Maher Aassi, Jose Fernando Molina, Oscar Massimiliano Epis Tags: Original Article Source Type: research